down arrow

Nkarta, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US65487U1088
USD
1.84
0.1 (5.75%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.751.85

52 Week

1.312.79
Valuation
Technical
Day's Volume

CASH

717.45 k

Shareholding (Mar 2025)

FII

6.47%

Held by 47 FIIs

DII

53.2%

Held by 31 DIIs

Promoter

19.34%

How big is Nkarta, Inc.?

22-Jun-2025

As of Jun 18, Nkarta, Inc. has a market capitalization of 128.43 million and reported net sales of 0.00 million with a net profit of -111.24 million for the latest four quarters. As of Dec 24, the company has shareholder's funds of 407.98 million and total assets of 501.20 million.

As of Jun 18, Nkarta, Inc. has a market capitalization of 128.43 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.00 million, while the sum of net profit for the same period is -111.24 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 407.98 million and total assets of 501.20 million.

Read More

What does Nkarta, Inc. do?

22-Jun-2025

Nkarta, Inc. is a biopharmaceutical company specializing in allogeneic, off-the-shelf engineered natural killer cell therapies for cancer treatment. It has a market cap of approximately $128.43 million and reported a net profit loss of $32 million as of March 2025.

Overview: <BR>Nkarta, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) and cell therapies to treat cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -32 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 128.43 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.69 <BR>Return on Equity: -29.37% <BR>Price to Book: 0.34<BR><BR>Contact Details: <BR>Address: 6000 Shoreline Court, Suite 102, SOUTH SAN FRANCISCO CA: 94080 <BR>Tel: 1 650 2150385 <BR>Website: https://www.nkartatx.com/

Read More

Who are in the management team of Nkarta, Inc.?

22-Jun-2025

As of March 2022, Nkarta, Inc.'s management team includes Dr. Ali Behbahani (Independent Chairman), Mr. Paul Hastings (CEO), and several independent directors: Dr. Tiba Aynechi, Mr. Fouad Azzam, Dr. Michael Dybbs, Dr. Simeon George, and Ms. Leone Patterson. The team features a blend of executive leadership and independent oversight.

As of March 2022, the management team of Nkarta, Inc. includes the following individuals:<BR><BR>- Dr. Ali Behbahani, who serves as the Independent Chairman of the Board and Director.<BR>- Mr. Paul Hastings, who is the President, Chief Executive Officer, and Director.<BR>- Dr. Tiba Aynechi, who is an Independent Director.<BR>- Mr. Fouad Azzam, who is also an Independent Director.<BR>- Dr. Michael Dybbs, serving as an Independent Director.<BR>- Dr. Simeon George, who is an Independent Director.<BR>- Ms. Leone Patterson, who is an Independent Director.<BR><BR>In summary, the management team consists of a mix of independent directors and key executive leadership.

Read More

Is Nkarta, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Nkarta, Inc. shows a mildly bullish technical trend, though it has significantly underperformed the S&P 500 with a year-to-date return of -20.08% compared to the index's 12.22%.

As of 9 September 2025, the technical trend for Nkarta, Inc. has changed from mildly bearish to mildly bullish. The MACD indicates a mildly bullish stance on both weekly and monthly time frames. The daily moving averages also reflect a mildly bullish position. However, the Bollinger Bands show a mixed signal with a bullish weekly outlook and a bearish monthly perspective. The KST is bullish weekly but bearish monthly, while the Dow Theory presents a mildly bearish weekly view contrasted by a mildly bullish monthly outlook. The OBV is mildly bearish weekly and mildly bullish monthly.<BR><BR>Despite the current mildly bullish technical stance, Nkarta has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -20.08% versus the S&P 500's 12.22%, and a one-year return of -62.24% compared to 17.14% for the index.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 151 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.79

stock-summary
Return on Equity

-30.54%

stock-summary
Price to Book

0.42

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-23 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.38%
0%
-12.38%
6 Months
3.95%
0%
3.95%
1 Year
-31.85%
0%
-31.85%
2 Years
-32.35%
0%
-32.35%
3 Years
-78.58%
0%
-78.58%
4 Years
-86.8%
0%
-86.8%
5 Years
-94.85%
0%
-94.85%

Nkarta, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Nkarta, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Nkarta, Inc. has changed from mildly bearish to mildly bullish. The MACD indicates a mildly bullish stance on both weekly and monthly time frames. The daily moving averages also reflect a mildly bullish position. However, the Bollinger Bands show a mixed signal with a bullish weekly outlook and a bearish monthly perspective. The KST is bullish weekly but bearish monthly, while the Dow Theory presents a mildly bearish weekly view contrasted by a mildly bullish monthly outlook. The OBV is mildly bearish weekly and mildly bullish monthly. Despite the current mildly bullish technical stance, Nkarta has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -20.08% versus the S&P 500's 12.22%, and a one-year return of -62.24% compared to 17.14% for the index....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
-211.76%
EBIT to Interest (avg)
-108.78
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.69
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.36
EV to EBIT
0.94
EV to EBITDA
1.02
EV to Capital Employed
-1.05
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-29.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 39 Schemes (20.9%)

Foreign Institutions

Held by 47 Foreign Institutions (6.47%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 8.00% vs 24.92% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-24.90",
          "val2": "-28.50",
          "chgp": "12.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.00",
          "val2": "-25.00",
          "chgp": "8.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 7.40% vs -3.25% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-119.00",
          "val2": "-125.80",
          "chgp": "5.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-108.80",
          "val2": "-117.50",
          "chgp": "7.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-24.90
-28.50
12.63%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-23.00
-25.00
8.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 8.00% vs 24.92% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-119.00
-125.80
5.41%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-108.80
-117.50
7.40%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 7.40% vs -3.25% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Nkarta, Inc. stock-summary
stock-summary
Nkarta, Inc.
Pharmaceuticals & Biotechnology
Nkarta, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) and cell therapies to treat cancer. Its modular NK cell engineering platform allows it to generate new product candidates. The Company’s engineered CAR-NK cells generally consist of an NK cell engineered with a targeting receptor, OX40 costimulatory domain, CD3z signaling moiety, and mbIL-15. This platform is modular, which enables optimization of different ways to enhance the natural signaling of engineered cells, as well as the ability to attach and optimize new targeting receptors. The Company’s lead product candidates are NKX101 and NKX019. The Company’s NK cell engineering platform is designed for engineering T cells and NK cells and understanding of NK cell biology.
Company Coordinates stock-summary
Company Details
6000 Shoreline Court, Suite 102 , SOUTH SAN FRANCISCO CA : 94080
stock-summary
Tel: 1 650 2150385
stock-summary
https://www.nkartatx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."